-
Product Insights
NewComputed Tomography (CT) Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Computed Tomography (CT) is a powerful, non-destructive evaluation technique used for producing 2D and 3D cross-sectional image of an object from a flat X-ray image. Computed Tomography (CT) is used on patients with a high risk of colon cancer, or full-motion heart scans for patients with high risk of heart disease. It can also be used for image complex fractures, detect infarction, tumors, calcifications, hemorrhage and bone trauma and also acute and chronic changes in the lung parenchyma etc. The...
-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report: Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months. Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, Identify themes that will have the greatest positive or negative impact in the coming months. Comprehend the opinions of industry respondents on these themes. Predict the industry’s growth prospects...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept in Retinopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept in Retinopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept in Retinopathy Drug Details: Aflibercept (Eylea) is a recombinant fusion protein...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crofelemer DR in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crofelemer DR in Irritable Bowel Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crofelemer DR in Irritable Bowel Syndrome Drug Details: Crofelemer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povetacicept in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povetacicept in Lupus Nephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povetacicept in Lupus Nephritis Drug Details: Povetacicept is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1019 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1019 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1019 in Pancreatic Cancer Drug Details: CBP-1019 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DR-0201 in Hematological Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DR-0201 in Hematological Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DR-0201 in Hematological Tumor Drug Details: DR-0201 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept in Graves' Ophthalmopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept in Graves' Ophthalmopathy Drug Details: Aflibercept (Eylea) is a recombinant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept in Optic Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept in Optic Neuropathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept in Optic Neuropathy Drug Details: Aflibercept (Eylea) is a recombinant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dimethyl Fumarate DR in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dimethyl Fumarate DR in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dimethyl Fumarate DR in Systemic Sclerosis (Scleroderma) Drug...